Publication details
Roční zkušenosti s Macugenem v léčbě vlhké formy VPMD
| Title in English | One year experience with Macugen in treatment of wet form of AMD |
|---|---|
| Authors | |
| Year of publication | 2008 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Pegaptanib (Macugen) is registrated for treatment of wet age related macular degeneration from August 2007. Pegaptanib is de facto first agent from group of antagonists of vascular endothelial growth factors. It inhibits specific isoform VEGF165. |